Literature DB >> 18806905

Botulinum toxin products overview.

A Carruthers1, J Carruthers.   

Abstract

The tremendous success of botulinum toxin type A (BOTOX(R), Allergan Inc.) in the cosmetic arena has acted as a stimulus for the development of other neurotoxins. After more than 2 decades of use, BOTOX(R) has become synonymous with wrinkle reduction and is considered to be the one of the most common non-surgical cosmetic procedures performed worldwide. Because of its vast popularity among patients seeking non-invasive methods to achieve facial rejuvenation, physicians from diverse specialties have integrated botulinum toxin injections into their existing practices. Herein, we present an overview of botulinum toxin products for cosmetic applications that have received regulatory approval or are under development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18806905

Source DB:  PubMed          Journal:  Skin Therapy Lett        ISSN: 1201-5989


  17 in total

1.  A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines.

Authors:  Matthias Imhof; Ulrich Kühne
Journal:  J Clin Aesthet Dermatol       Date:  2011-10

2.  Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25.

Authors:  Sheng Chen; Joseph T Barbieri
Journal:  J Biol Chem       Date:  2011-03-04       Impact factor: 5.157

Review 3.  Temporal characteristics of botulinum neurotoxin therapy.

Authors:  Frank J Lebeda; Regina Z Cer; Robert M Stephens; Uma Mudunuri
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

Review 4.  [New botulinum toxins for aesthetic dermatology : A comprehensive review].

Authors:  A Patil; M Kassir; U Wollina; M Goldust
Journal:  Hautarzt       Date:  2021-04-06       Impact factor: 0.751

Review 5.  Comparison and overview of currently available neurotoxins.

Authors:  Thomas J Walker; Steven H Dayan
Journal:  J Clin Aesthet Dermatol       Date:  2014-02

Review 6.  Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery.

Authors:  Erkan Kiris; Krishna P Kota; James C Burnett; Veronica Soloveva; Christopher D Kane; Sina Bavari
Journal:  Expert Rev Mol Diagn       Date:  2014-01-23       Impact factor: 5.225

Review 7.  Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction.

Authors:  Koenraad De Boulle; Steven Fagien; Boris Sommer; Richard Glogau
Journal:  Clin Interv Aging       Date:  2010-04-26       Impact factor: 4.458

Review 8.  Facial rejuvenation for middle-aged women: a combined approach with minimally invasive procedures.

Authors:  Alberto Goldman; Uwe Wollina
Journal:  Clin Interv Aging       Date:  2010-09-23       Impact factor: 4.458

9.  Small-molecule quinolinol inhibitor identified provides protection against BoNT/A in mice.

Authors:  Padma Singh; Manglesh Kumar Singh; Dilip Chaudhary; Vinita Chauhan; Pranay Bharadwaj; Apurva Pandey; Nisha Upadhyay; Ram Kumar Dhaked
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

Review 10.  Emerging opportunities for serotypes of botulinum neurotoxins.

Authors:  Zhongxing Peng Chen; J Glenn Morris; Ramon L Rodriguez; Aparna Wagle Shukla; John Tapia-Núñez; Michael S Okun
Journal:  Toxins (Basel)       Date:  2012-11-07       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.